<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="19864">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01719211</url>
  </required_header>
  <id_info>
    <org_study_id>1999-p-007948</org_study_id>
    <nct_id>NCT01719211</nct_id>
  </id_info>
  <brief_title>Genetic Basis of Mitral Valve Prolapse</brief_title>
  <acronym>MVP</acronym>
  <official_title>Genetic Basis of Mitral Valve Prolapse</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Leducq Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators have successfully identified two novel genetic loci for MVP on chromosomes
      11 and 13 and are searching for altered genes in these regions.  This requires recruiting
      large families who may have MVP linked to these or other chromosomes; and obtaining DNA
      samples from 1,000-1,500 individually affected patients to study the relation between DNA
      markers throughout the genome and MVP.  It is our expectation that the results of this study
      will lead to the discovery of gene(s) responsible for MVP.   This will lead to improved
      understanding of the disease and, in turn, improved ability to treat and prevent progression
      in genetically susceptible individuals.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a genome-wide association study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 1999</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Discovery of the genetic basis of Mitral Valve Prolapse</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Genome-wide association</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Mitral Valve Prolapse</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      DNA
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients referred for 2D echo for MVP
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Mitral valve prolapse

        Exclusion Criteria:

          -  Other mitral valve diseases
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>robert a levine, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mass General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Susan Slaugenhaupt, PhD</last_name>
    <phone>6176433217</phone>
    <email>slaugenhaupt@chgr.mgh.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Robert a levine, MD</last_name>
    <phone>6177241995</phone>
    <email>rlevine@partners.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mass General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <lastchanged_date>October 31, 2012</lastchanged_date>
  <firstreceived_date>October 30, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Robert A. Levine, MD</investigator_full_name>
    <investigator_title>Cardiologist</investigator_title>
  </responsible_party>
  <keyword>MVP, mitral valve</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Mitral Valve Prolapse</mesh_term>
    <mesh_term>Neurocirculatory Asthenia</mesh_term>
    <mesh_term>Orthostatic Intolerance</mesh_term>
    <mesh_term>Prolapse</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
